Alchemab Therapeutics Ltd
Registered name: ALCHEMAB THERAPEUTICS LTD
Alchemab Therapeutics Ltd made £30m revenue and £8.3m profit in the year to 31 Dec 2025.
Alchemab Therapeutics Ltd’s revenue was £30m in the year to 31 Dec 2025, with £8.3m profit and 55 employees. The company is classified under “research and experimental development on biotechnology” and is based in London; we hold 2 years of its filed accounts.
- Status
- Active
- Location
- London, London
- Age
- 7 yrs · since 2019
- Type
- Private Limited Company
Key figures
Badges are automated estimates derived from the filed figures — not statements of fact about the company.
Financial history
| Year to | 31 Dec 2023 | 31 Dec 2025 |
|---|---|---|
| Disclosure | Full P&L | Full P&L |
| Profit & loss | ||
| Revenue (turnover) | £0 | £30m |
| Operating profit | −£19.8m | £7.9m |
| Profit before tax | −£19.3m | £8.9m |
| Profit after tax | −£17.1m | £8.3m |
| Profit (best available) | −£17.1m | £8.3m |
| Employees (average) | 65 | 55 |
| Ratios | ||
| Profit margin | — | 27.7% |
| Revenue per employee | £0 | £546k |
| Profit per employee | −£263k | £151k |
| Balance sheet — indirect signals, not revenue | ||
| Net assets | — | — |
| Source | Accounts · bulk data Oct 2025 | Accounts · bulk data Sep 2026 |
How the business works
- Profit margin
- 27.7%
- Profit ÷ revenue.
- Gross margin
- —
- Gross profit ÷ revenue. High for software and services.
- Revenue per employee
- £546k
- Revenue ÷ average employees.
- Profit per employee
- £151k
- Profit ÷ average employees.
- Cash conversion
- —
- Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
- Fixed assets ÷ revenue
- —
- Capital intensity. Low = capital-light, cheaper to start.
- Deferred income ÷ revenue
- —
- Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
- Debtors ÷ revenue
- —
- Money owed by customers. Low = customers pay quickly.
Balance-sheet signals
Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.
- Net assets
- —
- Now —
- Cash at bank
- —
- Now —
- Headcount
- —
- Now 55
- Deferred income
- —
- Now —
- Fixed assets
- —
- Now —
Similar profitable businesses
- Amphista Therapeutics LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £33.9m
- Profit
- £19.8m
- Staff
- 56
- Novogene (UK) Company LimitedCambridge · Research and experimental development on biotechnology
- Revenue
- £38.2m
- Profit
- £2.8m
- Staff
- 68
- Sitryx Therapeutics LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £23.3m
- Profit
- £4.7m
- Staff
- —
- Charles River U.K. LimitedKent · Research and experimental development on biotechnology
- Revenue
- £22.2m
- Profit
- £18.8m
- Staff
- 129
- Origio LimitedFareham · Research and experimental development on biotechnology
- Revenue
- £20.1m
- Profit
- £499k
- Staff
- 82
- Enara Bio LimitedOxford · Research and experimental development on biotechnology
- Revenue
- £17.4m
- Profit
- £1.3m
- Staff
- 54
Sources
Latest figures from accounts for the year to 31 Dec 2025 (profit £8.3m), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.
Updated from Companies House on 15 Oct 2026
Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.